ART5 is designed to address the most common root cause of ADPKD by targeting PKD1, potentially restoring PC1 production in approximately 85% of patientsFirst-in-human SAD study in healthy volunteers ...
Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital ...
The government wants to abolish leasehold, but replacing it could prove far more complicated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results